Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.

This week, Novo Nordisk announced that people taking its mega-dose version of semaglutide lost substantially more body weight than usual in a large-scale trial. Novo Nordisk’s STEP UP trial ...

At baseline, a physical examination and laboratory tests were conducted. An eleven-week semaglutide drug dose titration period was started, and during this period, all participants continued using ...

Novo Nordisk has shared positive headline results from a late-stage study evaluating a higher dose of its GLP-1 receptor agonist semaglutide in adults with obesity. The phase 3b STEP UP trial has been ...